The FDA announced it has approved the abbreviated new drug application for pioglitazone, indicated for the treatment of type 2 diabetes in addition to diet and exercise.
eHealthcare Solutions (EHS) manages advertising on this website.
We use cookies to ensure that we give you the best experience on our website.
By continuing, you agree to the use of cookies as per the EHS Privacy Policy